ArticleFrontiers in pharmacology2023

Disitamab vedotin in combination with immune checkpoint inhibitors for locally and locally advanced bladder urothelial carcinoma: a two-center's real-world study.

Yongbao Wei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.